Xenetic Biosciences (XBIO) FCF Margin (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly FCF Margin came in at 66.47% in Q1 2026, up 10241.0% YoY from N/an in Q1 2025, and up 8.49% on a QoQ basis from 72.64% in Q4 2025.
Xenetic Biosciences (XBIO) FCF Margin (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of FCF Margin data on file, last reported at 66.47% in Q1 2026.
- Quarterly FCF Margin rose 10241.0% year-over-year to 66.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66.93% (up 879.0% YoY) and the FY2025 annual result came in at 76.83%, up 769.0% from the prior year.
- FCF Margin improved to 66.47% in Q1 2026, from 72.64% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 4.69% in Q4 2024 to a low of 537.43% in Q1 2022.
- A 5-year average of 151.64% and a median of 145.24% in 2023 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 47047 bps — and 2024, when it slumped 8172 bps.
- Tracing XBIO's FCF Margin over 5 years: stood at 84.6% in 2022, then plunged by 95 bps to 164.73% in 2023, then surged by 103 bps to 4.69% in 2024, then sank by 1648 bps to 72.64% in 2025, then rose by 8 bps to 66.47% in 2026.
- The last three FCF Margin figures came in at 66.47% (Q1 2026), 72.64% (Q4 2025), and 64.1% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | -132.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -132.53% |
| Mar 31, 2026 | -66.47% |
| Dec 31, 2025 | -72.64% |
| Sep 30, 2025 | -64.10% |
| Jun 30, 2025 | -65.07% |
| Mar 31, 2025 | -168.88% |
| Dec 31, 2024 | 4.69% |
| Sep 30, 2024 | -74.73% |
| Jun 30, 2024 | -72.29% |
| Mar 31, 2024 | -226.96% |
| Dec 31, 2023 | -164.73% |
| Sep 30, 2023 | -155.38% |
| Jun 30, 2023 | -173.44% |
| Mar 31, 2023 | -145.24% |
| Dec 31, 2022 | -84.60% |
| Sep 30, 2022 | -336.32% |
| Jun 30, 2022 | -174.23% |
| Mar 31, 2022 | -537.43% |
| Dec 31, 2021 | -555.07% |
| Sep 30, 2021 | -295.87% |